AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (currently amended) An intraluminal device, suitable for implantation in a body, which device is provided with a ~~synthetic~~ coating, wherein the ~~synthetic~~ coating comprises:

50-97% heparan sulfate;

1-20% laminin; and

0.2-15% type IV collagen.

2. (currently amended) The intraluminal device according to claim 1, wherein the coating ~~synthetic~~ comprises:

75-95% heparan sulfate;

3-10% laminin; and

0.5-10% type IV collagen.

3. (canceled)

4. (currently amended) The intraluminal device according to claim 1, wherein the ~~synthetic~~ coating further comprises a growth factor.

5. (previously presented) The intraluminal device according to claim 4, wherein the growth factor is selected from the group consisting of bFGF, IGF, TGF-β and VEGF.

6. (currently amended) An intraluminal device, suitable for implantation in a body, the device being provided with a ~~synthetic~~ coating that comprises:

50-97% heparan sulfate;

1-20% laminin;

0.2-15% type IV collagen; and

an antibiotic.

7. (currently amended) An intraluminal device, suitable for implantation in a body, the device being provided with a ~~synthetic~~ coating that comprises:

50-97% heparan sulfate;

1-20% laminin;

0.2-15% type IV collagen; and

an antibiotic comprising gentamycine.

8. (currently amended) The intraluminal device according to claim 1, wherein the ~~synthetic~~ coating further comprises vitronectine.

9. (currently amended) The intraluminal device according to claim 1, wherein the ~~synthetic~~ coating comprises:

85-95% heparan sulfate;

5-6% laminin;

3-4% type IV collagen;

0.5-1.5% entactin and nidogen;

0.001-1% growth factors; and

0.001-1% antibiotic.

10. (previously presented) The intraluminal device according to claim 1, wherein the intraluminal device is a prosthesis that comprises a stent or a graft.

11. (previously presented) A coating suitable for the intraluminal device according to claim 1.

12. (currently amended) A method for preparing an intraluminal device, comprising the steps of:

- providing an intraluminal device for implantation in a body;

- preparing a ~~synthetic~~ composition, comprising, in about 50 mg/ml solvent:

50-97% heparan sulfate;

1-20% laminin;

0.2-15% type IV collagen; and

the solvent being a suitable buffer or water;

- dipping the intraluminal device in the composition; and

- drying the dipped intraluminal device.

13. (currently amended) The method according to claim 12, wherein the ~~synthetic~~ composition further comprises entactin and nidogen.

14. (currently amended) The method according to claim 12, wherein the ~~synthetic~~ composition further comprises a growth factor, selected from the group consisting of bFGF, IGF, TGF-β and VEGF.

15. (currently amended) The method according to claim 12, wherein the ~~synthetic~~ composition further comprises an antibiotic.

16. (currently amended) The method according to claim 12, wherein the ~~synthetic~~ composition further comprises vitronectin.

17. (currently amended) The method according to claim 12, wherein the ~~synthetic~~ composition comprises:

85-95% heparan sulfate;

5-6% laminin;

3-4% type IV collagen;

0.5-1.5% entactin and nidogen;

0.001-1% growth factors; and

0.001-1% antibiotic.

18. (currently amended) The intraluminal device according to claim 1, wherein the ~~synthetic~~ coating further comprises entactin and nidogen.